Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice.
Learning and behavioral abnormalities are among the most common clinical problems in children with the neurofibromatosis-1 (NF1) inherited cancer syndrome. Recent studies using Nf1 genetically engineered mice (GEM) have been instructive for partly elucidating the cellular and molecular defects underlying these cognitive deficits; however, no current model has shed light on the more frequently encountered attention system abnormalities seen in children with NF1. Using an Nf1 optic glioma (OPG) GEM model, we report novel defects in non-selective and selective attention without an accompanying hyperactivity phenotype. Specifically, Nf1 OPG mice exhibit reduced rearing in response to novel objects and environmental stimuli. Similar to children with NF1, the attention system dysfunction in these mice is reversed by treatment with methylphenidate (MPH), suggesting a defect in brain catecholamine homeostasis. We further demonstrate that this attention system abnormality is the consequence of reduced dopamine (DA) levels in the striatum, which is normalized following either MPH or l-dopa administration. The reduction in striatal DA levels in Nf1 OPG mice is associated with reduced striatal expression of tyrosine hydroxylase, the rate-limited enzyme in DA synthesis, without any associated dopaminergic cell loss in the substantia nigra. Moreover, we demonstrate a cell-autonomous defect in Nf1+/- dopaminergic neuron growth cone areas and neurite extension in vitro, which results in decreased dopaminergic cell projections to the striatum in Nf1 OPG mice in vivo. Collectively, these data establish abnormal DA homeostasis as the primary biochemical defect underlying the attention system dysfunction in Nf1 GEM relevant to children with NF1.
Brown
Jacquelyn A
JA
Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Emnett
Ryan J
RJ
White
Crystal R
CR
Yuede
Carla M
CM
Conyers
Sara B
SB
O'Malley
Karen L
KL
Wozniak
David F
DF
Gutmann
David H
DH
D000818:Animals; D001288:Attention; D001289:Attention Deficit Disorder with Hyperactivity / Q000235:genetics*; D001921:Brain / Q000378:metabolism; D002648:Child; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000235:genetics / Q000378:metabolism*; D016514:Genes, Neurofibromatosis 1; D006801:Humans; D007980:Levodopa / Q000235:genetics / Q000378:metabolism; D008774:Methylphenidate / Q000378:metabolism / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008817:Mice, Mutant Strains; D008822:Mice, Transgenic; D009043:Motor Activity / Q000235:genetics; D009456:Neurofibromatosis 1 / Q000201:enzymology / Q000235:genetics* / Q000378:metabolism*; D025542:Neurofibromin 1 / Q000235:genetics / Q000378:metabolism; D009474:Neurons / Q000378:metabolism; D020339:Optic Nerve Glioma / Q000235:genetics / Q000378:metabolism; D013378:Substantia Nigra / Q000378:metabolism
D025542:Neurofibromin 1; D008774:Methylphenidate; D007980:Levodopa; D004298:Dopamine
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7925-30
12792021
Neurology. 1997 Apr;48(4):1121-7
9109916
Brain Res Bull. 2010 Oct 30;83(5):266-71
20615455
Neurobiol Dis. 2004 Dec;17(3):403-14
15571976
Dev Med Child Neurol. 2002 Mar;44(3):164-70
12005317
Am J Dis Child. 1989 Jul;143(7):833-7
2500844
Cell Stem Cell. 2007 Oct 11;1(4):443-57
18371380
PLoS One. 2009;4(5):e5464
19421325
Mol Cell Biol. 2002 Jul;22(14):5100-13
12077339
J Child Adolesc Psychopharmacol. 2006 Dec;16(6):687-98
17201613
Nat Genet. 1997 Mar;15(3):281-4
9054942
Behav Genet. 2006 Sep;36(5):660-4
16474913
Exp Neurol. 2002 Oct;177(2):461-74
12429192
Nat Neurosci. 2010 Jan;13(1):133-40
20023653
J Neurosci Methods. 2007 Jan 30;159(2):291-9
16949674
Genes Dev. 1994 May 1;8(9):1019-29
7926784
Neurobiol Dis. 2009 Sep;35(3):426-32
19524672
Cell. 1995 Dec 29;83(7):1197-209
8548806
Curr Biol. 2005 Nov 8;15(21):1961-7
16271875
Neuroimage. 2007 May 1;35(4):1434-7
17383899
Behav Brain Res. 2002 Mar 10;130(1-2):141-8
11864730
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4611-6
15557474
Neuropsychopharmacology. 2008 Feb;33(3):619-26
17487226
C R Seances Soc Biol Fil. 1998;192(6):1127-37
10101608
Dev Med Child Neurol. 2004 Aug;46(8):553-63
15287247
J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S46-53
18480677
J Neurosci. 2010 Apr 21;30(16):5579-89
20410111
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4436-41
20176946
Prog Brain Res. 2008;172:543-65
18772050
Neurosci Biobehav Rev. 2000 Jan;24(1):59-71
10654662
J Dev Behav Pediatr. 1996 Aug;17(4):229-39
8856518
J Neurosci. 2006 Mar 15;26(11):2841-51
16540561
Curr Neurol Neurosci Rep. 2003 Mar;3(2):129-36
12583841
Neurology. 2005 Oct 11;65(7):1037-44
16217056
Cancer Res. 2003 Dec 15;63(24):8573-7
14695164
Neuroscience. 2005;135(2):545-54
16111820
Stress. 2007 Jun;10(2):121-30
17514580
Cancer Res. 2008 Mar 1;68(5):1520-8
18316617
J Neurooncol. 2005 May;72(3):245-53
15937648
Am J Med Genet A. 2003 Jul 30;120A(3):326-30
12838550
Dev Med Child Neurol. 2006 Dec;48(12):973-7
17109785
Med Pediatr Oncol. 2003 Jan;40(1):26-34
12426683
Brain Res Brain Res Protoc. 2005 Dec;16(1-3):10-9
16185914
J Intellect Disabil Res. 2005 Jan;49(Pt 1):33-46
15634310